Fast Five Quiz: Check Your Knowledge of Prostate Cancer

Bradley Schwartz, DO


February 21, 2019

The USPSTF recommends PSA-based screening for prostate cancer in men aged 55-69 years on an individualized basis. This is because findings suggest that more men will be harmed by this testing than will benefit. Overtreatment based on PSA test screening results may lead to erectile dysfunction, urinary incontinence, bowel control problems, and a small risk for death and serious complications from surgery. Although both DRE and PSA-based testing are used to screen for prostate cancer, the USPSTF recommendations primarily focus on PSA screening, with or without DRE. The USPSTF has not recommended DRE screening alone for prostate cancer.

For more on PSA screening, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: